Found 491 clinical trials
EAS Familial Hypercholesterolaemia Studies Collaboration
Familial hypercholesterolaemia (FH) is a common genetic disorder resulting in marked elevations in low-density lipoprotein cholesterol (LDL-C). If untreated, lifelong exposure to elevated LDL-C results in a substantially increased risk of (premature) cardiovascular disease as compared to the general population. Although FH adverse cardiovascular outcomes are potentially preventable through early …
- 0 views
- 16 Feb, 2024
- 1 location
Characterization of Novel Lipoprotein Properties Associated With an Increased Risk to Develop Atherosclerosis
Objectives of Medical Research: Separation of LDL and HDL from blood samples of patients with high LDL and / or low HDL who have developed atherosclerotic disease with similar patients who have no evidence of atherosclerosis. Lipidomics and proteomics will examine whether there is a difference in lipid and protein …
- 0 views
- 05 Aug, 2020
Observation of Blood Lipid Outcomes in Lipid Clinic
Taipei MacKay Memorial Hospital will establish a Lipid Clinic for hyperlipidemic patients. In this Lipid Clinic, the physician will discuss with each individual patient and set an individualized LDL goal according to current guideline and regulation of National Health Insurance Administration (NHIA). The aim of this study is to observe …
- 0 views
- 16 Feb, 2024
- 1 location
Differential Diagnosis and Risk Stratification in Patients With Suspected NSTEACS
To evaluate possibilities of rapid differential diagnosis and risk stratification in patients urgently admitted to the CCU with a suspected acute coronary syndrome without persistent ST-segment elevation (NSTEACS).
- 0 views
- 16 Feb, 2024
- 1 location
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS-NIS) (MARS)
Primary objectives: To assess the effectiveness of the PRALUENT® 2 ml SYDNEY auto-injector as measured by the lipid-lowering effect of alirocumab after approx. 12 weeks treatment To assess the treatment satisfaction, as well as patient adherence and persistence after approximately 12 weeks of treatment with the PRALUENT® 2 ml SYDNEY …
- 0 views
- 19 Sep, 2022
- 1 location
Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS-NIS) (MARS)
Primary objectives: To assess the effectiveness of the PRALUENT® 2 ml SYDNEY auto-injector as measured by the lipid-lowering effect of alirocumab after approx. 12 weeks treatment To assess the treatment satisfaction, as well as patient adherence and persistence after approximately 12 weeks of treatment with the PRALUENT® 2 ml SYDNEY …
- 0 views
- 19 Sep, 2022
- 2 locations
Micronet Covered Stent in in Arterial Locations Beyond the Carotid Bifurcation - FLOW-Guard Study
Prospective observational study of MicroNet covered stent implantation in the elevated risk peripheral lesions (high lesion load, thrombus containing, highly calcified). Open-label, non randomized, single arm observational study. Jagiellonian University Medical College research project.
- 0 views
- 05 Aug, 2020
Early Detection of Familial Hypercholesterolemia in Children
Its early detection, would allow us to initiate lifestyle therapeutical changes and early pharmacological therapy if necessary. This is a key fact to reduce atherosclerosis progression and cardiovascular risk in adulthood. Moreover, it will allow, detecting the first and second degree affected relatives.
- 0 views
- 05 Aug, 2020
Decrease in Paraoxonase Enzyme Level and Myocardial nfarction
Numerous data on Paraoxonase-1 levels have been found in studies, especially with decreasing serum paraoxonase and arylesterase activities with age, associated with increased risk of systemic oxidative stress and atherosclerosis in humans. Many studies have shown that serum Paraoxonase-1 activity is significantly reduced in people with myocardial infarction, dyslipidemia, atherosclerosis, …
- 0 views
- 16 Feb, 2024
- 1 location
Cardiac Biomarkers in Preeclampsia: Prediction of Disease and the Risk of Future Cardiovascular Events in Survivors
Conclusion: Myocardial ischemia, myocardial infarction and stroke are major causes of sudden death because their precursors; atherosclerosis and hypertension are asymptomatic. Under-utilization of routine health care check further increases the risk of sudden death from these conditions.
- 0 views
- 16 Feb, 2024
- 1 location